CrystalGenomics Inc

CrystalGenomics, Inc. is a biopharmaceutical company based in Seongnam, South Korea, that discovers and develops structural chemoproteiomics-based drugs. Its lead candidate is CG100649, a tissue-specific NSAID with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa trials. Other candidates include CG200745, a histone deacetylase inhibitor for cancer in Phase I, and CG400549, an antibiotic for MRSA and VRSA in Phase I. The company also provides protein services and has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. Founded in 2000, it is headquartered in Seongnam, South Korea.